Futura Medical PLC
LSE:FUM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Futura Medical PLC
LSE:FUM
|
UK |
|
Cypherpunk Holdings Inc
OTC:CYFRF
|
CA |
|
EQTEC PLC
LSE:EQT
|
IE |
|
Industrial & Infrastructure Fund Investment Corp
TSE:3249
|
JP |
|
H
|
Hangzhou Flariant Co Ltd
SSE:605566
|
CN |
|
M
|
Mutuagung Lestari Tbk PT
IDX:MUTU
|
ID |
|
S
|
Sree Rayalaseema Hi-Strength Hypo Ltd
NSE:SRHHYPOLTD
|
IN |
|
Hanjin Kal
KRX:180640
|
KR |
|
C
|
Collective Audience Inc
NASDAQ:CAUD
|
US |
|
F
|
Flamemaster Corp
OTC:FAME
|
US |
|
Rover Metals Corp
F:4XO0
|
CA |
|
A
|
AJ Networks Co Ltd
KRX:095570
|
KR |
Futura Medical PLC
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
